A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2012
At a glance
- Drugs BMS 986094 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 03 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 31 Mar 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
- 01 Sep 2010 The actual patient number (n=42) was reported in an Inhibitex media release. Inhibitex also plans to present detailed results at an upcoming scientific meeting.